(AstraZeneca) Mar 30, 2020 - AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC) chemotherapies, etoposide plus either carboplatin or cisplatin (platinum-etoposide). The approval by the Food and Drug Administration was based on positive results from the Phase III CASPIAN trial showing Imfinzi in combination with SoC platinum-etoposide demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus SoC alone.Read Article
H. Jack West, MD (Posted: March 30, 2020)
This provides another option that is pretty much a lateral move compared to atezolizumab with chemo in the IMpower133 trial. Both efficacy and tolerability data appear very similar. One modest difference is that the CASPIAN trial gave durvalumab with a chemo regimen of either cisplatin or carboplatin along with etoposide, while the IMpower133 chemo backbone was carbo/etoposide only. Accordingly, for those who routinely favor a cisplatin-containing regimen in extensive SCLC, the FDA approval of the CASPIAN regimen may resonate more for them.